Haemophilia therapies

Bibliography

• MANNUCCI PM, TUDDENHAM EG: The hemophilias-from royal genes to gene therapy. N. Engl. J. Med. (2001) 344:1773-1780.
   PubMed Web of Science ®Google Scholar
• ROSNER F: Haemophilia in the Talmud and rabbinic writings. Ann. Intern. Med. (1969) 70:833-837.
   PubMed Web of Science ®Google Scholar
• LANE S: Haemorrhagid diathesis. Successful transfusion of blood. Lancet (1840) 1:185-188.
   Google Scholar
• PAYNE WW, STEEN RE: Haemostatic therapy in haemophilia. Br. Med. J. (1929) 29(1):1150-1152.
   Google Scholar
• BRINKHOUS KM: A study of the clotting defect in hemophilia : the delayed formation of thrombin. Am. J. Med. Sci. (1939) 198:509-516.
   Google Scholar
• BIGGS R, DOUGLAS AS, MACFARLANE RG, DACIE JV, PITNEY WR, MERSKEY C: Christmas disease: a condition previously mistaken for hemophilia. Br. Med. J. (1952) 2:1378-1382.
   PubMed Web of Science ®Google Scholar
• CRAMER R, FLÜCKIGER P, GASSER C, KOLLER F, LOELIGER A, MATTER M: Two cases of hereditary hemophilia due to a deficiency of a new clotting factor (Christmas factor). Acta Haematol. (1953) 10:65-76.
   Web of Science ®Google Scholar
• MANNUCCI PM: AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J. Thromb. Haemost. (2003) 1:2065-2069.
   PubMed Web of Science ®Google Scholar
• EVATT BL, FARUGGIA A, SHAPIRO AD, WILDE JT: Haemophilia 2002: emerging risks of treatment. Haemophilia (2002) 8:221-229.
   PubMed Web of Science ®Google Scholar
• ROYAL S, SCHRAMM W, BERNTORP E et al.: Quality of life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 8:44-50.
   PubMed Web of Science ®Google Scholar
• MANNUCCI PM: Haemophilia:treatment options in the twenty-first century. J. Thromb. Haemost. (2003) 1:1349-1355.
   PubMed Web of Science ®Google Scholar
• BURNOUF T, RADOSEVICH M: Nanofiltration of plasma derived biopharmaceutical products. Haemophilia (2003) 9:24-37.
   PubMed Web of Science ®Google Scholar
• BUSCH MP, KLEINMAN SH, JACKSON B, STRAMER SL, HEWLETT I, PRESTON S: Commitee report. Nucleic acid testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational task force on nucleic acis amplification testing of blood donors. Transfusion (2000) 40:143-159.
   PubMed Web of Science ®Google Scholar
• GOUDEMAND J, ROTSCHILD C, DEMIGUEL V et al.: Influence of the type of Factor VIII concentrate on the incidence of Factor VIII inhibitors in previously untreated patients with severe hemophilia A. FVIII-LFB and Recombinant FVIII Study Groups. Blood (2006) 107:46-51.
   PubMed Web of Science ®Google Scholar
• BEHRMANN M, PASI J, SAINT-REMY JM et al.: Von Willebrand factor modulates Factor VIII immunogenicity: comparative study of different Factor VIII concentrates in a haemophilia A mouse model. Thromb. Haemost. (2002) 88:221-229.
   PubMed Web of Science ®Google Scholar
• KERNOFF PB, DURANT IJ, RIZZA CR, WRIGHT FB: Severe allergic pulmonary oedema after plasma transfusion. Br. J. Haematol. (1972) 23:777-781.
   PubMed Web of Science ®Google Scholar
• GIANGRANDE PLF: Treatment of haemophilia: recombinant factors only? Yes. J. Thromb. Haemost. (2003) 1:214-215.
   PubMed Web of Science ®Google Scholar
• GITSCHIER J, WOOD WI, GORALKA TM et al.: Characterization of the human Factor VIII gene. Nature (1984) 312:326-330.
   PubMed Web of Science ®Google Scholar
• TOOLE JT, KNOPF JL, WOZNEY JM et al.: Molecular cloning of a cDNA encoding human anti-haemophilic factor. Nature (1984) 312:342-347.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ RS, ABILDGAARD CF, ALEDORT LM et al.: Human recombinant DNA-derived antihaemophilic factor (Factor VIII) in the treatment of haemophilia A. N. Engl. J. Med. (1990) 323:1800-1805.
   PubMed Web of Science ®Google Scholar
• BOEDEKER BG: Production processes of licensed recombinant factor FVIII preparations. Semin. Thromb. Haemost. (2001) 274:385-394.
   Google Scholar
• BRINKHOUS K, SANDBERG H, WIDLUND L et al.: Preclinical pharmacology of albumin-free B domain deleted recombinant Factor VIII. Semin. Thromb. Haemost. (2002) 28:269-272.
   PubMed Web of Science ®Google Scholar
• TOOLE JT, PITTMAN DD, ORR EC et al.: A large region (=95kDa) of human Factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA (1986) 83:5839-5842.
   Google Scholar
• LUSHER JM, LEE CA, KESSLER CM, BEDROSIAN CL: The safety and efficacy of B domain deleted recombinant Factor VIII concentrate in patients with severe haemopihilia A. For the REFACTO 3 Study Group. Haemophilia (2003) 9:38-49.
   PubMed Web of Science ®Google Scholar
• GRUPPO RA, BROWN D, WILKES MM, NAVICKIS RJ: Increased breaktrough bleeding during prophylaxis with B-domain deleted Factor VIII – a robust meta-analytic finding. Haemophilia (2004) 10:449-451.
   PubMed Web of Science ®Google Scholar
• MITTERER A, KALIWODA M, KUMAR HP, KASHI RS: Recombinant Factor VIII manufactured without the use of animal/human derived substances (rAHF-PFM). Blood (2002) 100:92b (Abstract).
   Web of Science ®Google Scholar
• CHOO KH, GOULD KG, REES DJ, BROWNLEE GG: Molecular cloning of the gene for human anti-haemophilic Factor IX. Nature (1982) 299(5879):178-180.
   PubMed Web of Science ®Google Scholar
• ANSON DS, CHOO KH, REES DJ et al.: The gene structure of human anti-haemophilic Factor IX. EMBO J. (1984) 3:1053-1060.
   PubMed Web of Science ®Google Scholar
• HAASE M: Human recombinant Factor IX: safety and efficacy studies in haemophilia B patients previously treated with plasma derived Factor IX concentrates. Blood (2002) 100:4242; author reply 4242-4243.
   PubMedGoogle Scholar
• WHITE G, SHAPIRO A, RAGNI M et al.: Clinical evaluation of recombinant Factor IX. Semin. Hematol. (1998) 35(Suppl. 2):33-38.
   PubMed Web of Science ®Google Scholar
• WHITE GC II, COURTER S, BRAY GL, LEE M, GOMPERTS ED: A multicentre study of recombinant Factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb. Haemost. (1997) 77:660-667.
   PubMed Web of Science ®Google Scholar
• SCHARRER I, BRAY GL, NEUTZLING O: Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived FVIII concentrates. Haemophilia (1999) 5:145-154.
   PubMed Web of Science ®Google Scholar
• BRAY GL, GOMPERTS ED, COURTER S et al.: A multicentre study of recombinant Factor VIII (Recombinate): safety, efficacy and inhibitor risk in perviously untreated patients with haemophilia A. Blood (1994) 83:2428-2435.
   PubMed Web of Science ®Google Scholar
• LUSHER JM, ARKIN S, ABILGAARD CF: Kogenate previously untreated patient study group. Recombinant afctor VIII for the treatment of previously untreated patients with haemophilia A: safety, efficacy and development of inhibitors. N. Engl. J. Med. (1993) 328:453-459.
   PubMed Web of Science ®Google Scholar
• EHRENFORTH S, KREUZ W, SCHARRER I et al.: Incidence of development of factor FVIII and FIX inhibitors in haemophiliacs. Lancet (1992) 339:594-598.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-MERCHAN EC: Orthopedic surgery in persons with haemophilia. Thromb. Haemost. (2003) 89:34-42.
   PubMed Web of Science ®Google Scholar
• FISCHER K, VAN DER BERG M: Prophylaxis for severe hamophilia: clinical and economical issues. Haemophilia (2003) 9:376-381.
   PubMed Web of Science ®Google Scholar
• PETRINI P, LINDVALL N, EGBERG N, BLOMBACK M: Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am. J. Pediatr. Hematol. Oncol. (1991) 13:280-287.
   PubMedGoogle Scholar
• LOFFQVIST T, NILSSON IM, BERNTORP E, PETTERSSON H: Haemophilia prophylaxis in young patients–a long term follow up. J. Intern. Med. (1997) 241:395-400.
   PubMed Web of Science ®Google Scholar
• FISCHER K, VAN DER BOM M, NEGRIER C et al.: Prophylactic versus on demand treatment strategies for severe haemophilia: a comparison of costs and long term outcome. Haemophilia (2002) 8:1365-2516.
   Google Scholar
• LJUNG RC: Prophylactic treatment in Sweden – overtreatment or optimal model? Haemophilia (1998) 4:409-412.
   PubMed Web of Science ®Google Scholar
• BERNTORP E, BOULYJENKOV V, BRETTLER D et al.: Modern treatment of haemophilia. Bull. World Health Organ. (1995) 73:691-701.
   PubMed Web of Science ®Google Scholar
• LJUNG R, VAN DER BERG M, PETRINI P et al.: Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Pediatr. (1998) 87:1051-1054.
   PubMed Web of Science ®Google Scholar
• TUSELL J, PEREZ-BIANCO R: Prophylaxis in developed and in emerging countries. Haemophilia (2002) 8:183-188.
   PubMed Web of Science ®Google Scholar
• FELDMAN BM, RIVARD G, ISRAELIS S et al.: Preliminary results from the Canadian hemophilia prophylaxis trial. Haemophilia (2000) 6:272.
   Google Scholar
• ALEDORT LM: Why thrombin generation? From bench to bedside. Pathophysiol. Haemost. Thromb. (2003) 33:2-3.
   PubMed Web of Science ®Google Scholar
• THE MEDICAL AND SCIENTIFICADVISORY COUNCIL (MASAC): MASAC Recommendations Concerning Prophylaxis. MASAC Document #170. 22 April 2006, and adopted by the National Hemophilia Foundation Board of Directors on 3 June 2006 (2006).
   Google Scholar
• KULKARNI R, PONDER KP, JAMES AH et al.: Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a white paper of the Perinatal Task Force of THE Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia (2006) 12:205-211.
   PubMed Web of Science ®Google Scholar
• VAN DER BERG HM, FISCHER K, ROSENDAAL G, MAUSER-BUNSCHOTEN EP: The use of the Port-A-Cath in children with haemophilia-a review. Haemophilia (1998) 4:418-420.
   PubMed Web of Science ®Google Scholar
• VIDLER V, RICHARDS M, VORA A: Central venous catheter associated thrombosis in severe haemophilia. Br. J. Haematol. (1999) 104:461-464.
   PubMed Web of Science ®Google Scholar
• BLANCHETTE VS, AL-TRABOLSI H, STAIN AM: High risk of central venous line-associated thrombosis in boys with hemophilia. Blood (1999) 94:818a (Abstract).
   PubMed Web of Science ®Google Scholar
• JOURNAYCAKE JM, QUINN CT, MILLER KL, ZAJAC JL, BUCHANAN GR: Catheter related deep venous thrombosis in children with hemophilia. Blood (2001) 98:1727-1731.
   PubMed Web of Science ®Google Scholar
• LJUNG R: Central venous lines in haemophilia. Haemophilia (2003) 9(Suppl. 1):88-93.
   PubMed Web of Science ®Google Scholar
• BOHN RL, AVORN J, GLYNN RJ, CHOODNOVSKIY I, HASCHEMEYER R, ALEDORT LM: Prophylactic use of Factor VIII: an economic evaluation. Thromb. Haemost. (1998) 79:932-937.
   PubMed Web of Science ®Google Scholar
• WIGHT J, PAISLEY S: The epidemiology of inhibitors in haemophilia A: a systemic review. Haemophilia (2003) 9:418-435.
   PubMed Web of Science ®Google Scholar
• ASTERMARK J: Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia (2006) 12(Suppl. 3):52-60.
   PubMed Web of Science ®Google Scholar
• SAINT REMY JM, LACROIX DESMAZES S, OLDENBURG J: Inhibitors in mhaemophilia: pathophysiology. Haemophilia (2004) 10(Suppl. 4):146-151.
   PubMed Web of Science ®Google Scholar
• WHITE GC II, KEMPTON CL, GRIMSLEY A, NIELSEN B, ROBERTS R: Cellular immune responses in haemophilia: why do inhibitors develop in some, but not all haemophiliacs? J. Thromb. Haemost. (2005) 3:1676-1681.
   PubMed Web of Science ®Google Scholar
• LEISSINGER CA: Prevention of bleeds in hemophilia patients with inhibitors:emerging data and clinical direction. Am. J. Hematol. (2004) 77:187-193.
   PubMed Web of Science ®Google Scholar
• ABILDGAARD CF, PENNER JA, WATSON-WILLIAMS EJ: Anti inhibitor coagulant complex (Autoplex) for treatment of Factor VIII inhibitors in haemophilia. Blood (1980) 56:978-984.
   PubMed Web of Science ®Google Scholar
• LUSHER JM, BLATT PM, PENNER JA et al.: Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute haemarthroses in haemophiliacs with inhibitors to Factor VIII. Blood (1983) 62:1135-1138.
   PubMed Web of Science ®Google Scholar
• TURECEK PL, VARADI K, GRITSCH H, SCHWARZ HP: Activated prothrombin complex concentrates induce haemostasis by a balanced effect at multiple sites of the coagulation pathway. Haemophilia (1998) 4:168 (Abstract).
   Google Scholar
• VON DEPKA M: Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia (2005) 11(Suppl. 1):18-23.
   PubMed Web of Science ®Google Scholar
• WILDE JT: Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiol. Haemost. Thromb. (2002) 32(Suppl. 1):9-12.
   PubMedGoogle Scholar
• SJAMSOEDIN LJ, HEIJNEN L, MAUSER-BUNSCHOTEN EP et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to FVIII. A double blind clinical trial. N. Engl. J. Med. (1981) 305:717-721
   PubMed Web of Science ®Google Scholar
• HILGARTNER MW,KNATTERUD GL: The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood (1983) 61:36-40.
   PubMed Web of Science ®Google Scholar
• HILGARTNER M, ALEDORT L, ANDES A, GILL J: Efficacy ans safety of vapour heated anti-inhibitor coagulant complex in haemophilia patients. FEIBA study group. Transfusion (1990) 30:626-630.
   PubMed Web of Science ®Google Scholar
• NEGRIER C, GOUDEMAND J, SULTAN Y, BERTRAND M, ROTHSCHILD C, LAUROUA P: Multicentre retrospective study on the utilization of FEIBA in France in patients with Factor VIII and Factor IX inhibitors. French FEIBA study Group. Factor Eight Bypassing Activity. Thromb. Haemost. (1997) 77:1113-1119.
   PubMed Web of Science ®Google Scholar
• HAY CR, BAGLIN TP, COLLINS PW et al.: The diagnosis and management of Factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br. J. Haematol. (2000) 111:78-90.
   PubMed Web of Science ®Google Scholar
• EHRLICH HJ, HENZL M, GOMPERTS ED: Safety of FVIII inhibitor bypass activity (FEIBA):10-year compilation of thrombotic adverse events. Haemophilia (2002) 8:83-90.
   PubMed Web of Science ®Google Scholar
• HAY CR, BAGLIN TP, COLLINS PW, HILL FG, KEELING DM: The diagnosis and management of Factor VIII and Factor IX inhibitors: a guideline from UK haemophilia center Doctors’ organisation (UKHCDO). Br. J. Haematol. (2000) 111:78-90.
   PubMed Web of Science ®Google Scholar
• HORWITH G, REVIE DR: Efficacy of viral clearance methods used in the manufacture of activated prothrombin complexe concentrates: focus on Autoplex T. Haemophilia (1999) 5(Suppl. 3):19-23.
   PubMedGoogle Scholar
• SJAMSOEDIN LJ, HEIJNEN L, MAUSER-BUNSCHOTEN EP et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to Factor VIII. N. Engl. J. Med. (1981) 305:717-721.
   PubMed Web of Science ®Google Scholar
• VARADI K, NEGRIER C, BERNTORP E et al.: Monitoring the bioavailability of FEIBA with a thrombin generation assay. J. Thromb. Haemost. (2003) 1:2374-2380.
   PubMed Web of Science ®Google Scholar
• DARGAUD Y, LIENHART A, MEUNIER S et al.: Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia (2005) 11(5):552-558.
   PubMed Web of Science ®Google Scholar
• YOUNG G, BLAIN R, NAKAGAWA P, NUGERT DJ: Individualization of bypassing agent treatment for hemophilic patients with inhibitors utilizing thromboelastography. Haemophilia (2006) 12:598-604.
   PubMed Web of Science ®Google Scholar
• MONROE DM, HOFFMAN M, OLIVER JA et al.: Platelet activity of high dose Factor VIIa is independent of tissue afctor. Br. J. Haematol. (1997) 99:542-547.
   PubMed Web of Science ®Google Scholar
• FRANCHINI M, ZAFFANELLO M, VENERI D: Recombinnat FVIIa. Thromb. Haemost. (2005) 93:1027-1035.
   PubMed Web of Science ®Google Scholar
• VAN’T VEER C, GOLDEN NJ, MANN KG: Inhibition of thrombin generation by the zymogen Factor VII: implications for the treatment of hemophilia A by Factor VIIa. Blood (2000) 95:1330-1335.
   PubMed Web of Science ®Google Scholar
• HOFFMAN M: A cell based model of haemostasis. Blood Rev. (2003) 17:S1-S5.
   PubMed Web of Science ®Google Scholar
• LISMAN T, MOSNIER LO, LAMBERT T et al.: Inhibition of fibrinolysis by recombinant Factor VIIa in plasma from patients with severe haemophilia A. Blood (2002) 99:175-179.
   PubMed Web of Science ®Google Scholar
• SHAPIRO A, GILCHRIST GS, HOOTS WK, COOPER HA, GASTINEAU DA: Prospective randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. (1998) 80:773-778.
   PubMed Web of Science ®Google Scholar
• LUSHER J, INGERSLEV J, ROBERTS H, HEDNER U: Clinical experience with recombinant Factor VIIa. Blood Coagul. Fibrinolysis (1998) 9:119-128.
   PubMed Web of Science ®Google Scholar
• SCHARRER I: Recombinate Factor VIIa for patients with inhibitors to Factor VIII or IX or Factor VII deficiency. Haemophilia (1999) 5:253-259.
   PubMed Web of Science ®Google Scholar
• INGERSLEV J: Efficacy and safety of recombinant Factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilia patients with Factor VIII and Factor IX inhibitors. Semin. Thromb. Haemost. (2000) 26:425-432.
   PubMed Web of Science ®Google Scholar
• HEDNER U, GLAZER S, FALCH J: Recombinant activated Factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus. Med. Rev. (1993) 7:78-83.
   PubMedGoogle Scholar
• SANTAGOSTINO E, GRINGERI A, MANNUCCI PM: Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. Br. J. Haematol. (1999) 104:22-26.
   PubMed Web of Science ®Google Scholar
• LAURIAN Y, GOUDEMAND J, NEGRIER C et al.: Use of recombinant activated Factor VII as first line therapy for bleeding episodes in haemophilaics with Factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul. Fibrinolysis (1998) 9:S107-S110.
   PubMed Web of Science ®Google Scholar
• KEY NS, ALEDORT LM, BEARDSLEY D et al.: Home treatment of mild to moderate bleeding episodes using recombinant activated Factor VII (Novoseven) in haemophiliacs with inhibitors. Thromb. Haemost. (1998) 80:912-918.
   PubMed Web of Science ®Google Scholar
• LLOYDS-JONES M, WIGHT J, PAISLEY S, KNIGHT C: Control of bleeding in patients with haemophilia A with inhibitors:a systematic review. Haemophilia (2003) 9:464-520.
   PubMed Web of Science ®Google Scholar
• JURLANDER B, THIM L, KLAUSEN NK et al.: Recombinant activated Factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin. Thromb. Haemost. (2001) 27:373-383.
   PubMed Web of Science ®Google Scholar
• SIDDIQUI MA, SCOTT LJ: Recombinant Factor VIIa (eptacog alfa). A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs (2005) 65:1161-1177.
   PubMed Web of Science ®Google Scholar
• KENET G, LUBETSKY A, LUBOSHITZ J et al.: A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated Factor VII (Novoseven). J. Thromb. Haemost. (2003) 1:450-455.
   PubMed Web of Science ®Google Scholar
• PARAMESWARAN R, SHAPIRO AD, GILL JC, KESSLER CM: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society. HTRS Registry Investigators. Haemophilia (2005) 11:100-106.
   PubMed Web of Science ®Google Scholar
• KAVAKLI K, MAKRIS M, ZULFIKAR B, ERHARDTSEN E, ABRAMS ZS, KENETT G: Home treatment of haemarthroses using a single dose regimen of recombinant activated afctor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. NovoSeven Trial (F7 HEAM-510) Investigators. Thromb. Haemost. (2006) 95:600-605.
   PubMed Web of Science ®Google Scholar
• SCHULMAN S, BECH-JENSEN M, VARON D et al.: Feasibility of using recombinant Factor VIIa in continuous infusion. Thromb. Haemost. (1996) 75:432-436.
   PubMed Web of Science ®Google Scholar
• LUDLAM CA, SMITH MP, MORFINI M et al.: A prospective study of recombinant activated Factor VII administered by continuous infusion to inhibitor patients undergoing elective major otrhopaedic surgery: a pharmacokinetic and efficacy evaluation. Br. J. Haematol. (2003) 120:808-813.
   PubMed Web of Science ®Google Scholar
• SANTAGOSTINO E, MORFINI M, ROCINO A et al.: Relationship between Factor VII activity and clinical efficacy of recombinant afctor VIIa given by continuous infusion to patients with Factor VIII inhibitors. Thromb. Haemost. (2001) 86:954-958.
   PubMed Web of Science ®Google Scholar
• SORENSEN B, INGERSLEV J: Whole blood clot formation phenotypes in haemophilia A and rare coagulation disorders. Patterns of response to recombinant Factor VIIa. J. Thromb. Haemost. (2004) 2:102-110.
   PubMed Web of Science ®Google Scholar
• DARGAUD Y, BORDET JC, TRZECIAK MC, VINCIGUERRA C, NEGRIER C: A case of Glanzmann’s thrombasthenia successfully treated with recombinant FVIIa during a surgical procedure: observations on the monitoring and the mechanismof action of this drug. Haematologica (2006) 91(1):17-20.
   PubMed Web of Science ®Google Scholar
• FULCHER CA, DE GRAAF MAHONEY S, ZIMMERMANN TS et al.: FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood (1987) 69:1475-1480.
   PubMed Web of Science ®Google Scholar
• FREEDMAN J, GARVEY MB: Immunoadsorption of Factor VIII inhibitors. Curr. Opin. Hematol. (2004) 11:327-333.
   PubMed Web of Science ®Google Scholar
• RIVARD GE: Use of protein A column and porcine Factor VIII. Haemophilai (2002) 8(Suppl. 1):20-23.
   PubMed Web of Science ®Google Scholar
• BRACKMANN HH, GORMSEN J: Massive Factor VIII infusion in haemophiliac with Factor VIII inhibitor, high responder. Lancet (1977) 2(8044):933.
   PubMed Web of Science ®Google Scholar
• MORFINI M, LEE M, MESSORI A: The design and analysis of half-life and recovery studies for Factor VIII and Factor IX. Factor VIII/Factor IX Scientific and Standardization Commitee of the International Society for Thrombosis and Haemostasis. Thromb. Haemost. (1991) 66:384-386.
   PubMed Web of Science ®Google Scholar
• DIMICHELE DM, KRONER B; THE NORTH AMERICAN IMMUE TOLERANCE STUDY GROUP: The North American Immue Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost. (2002) 87:52-57.
   PubMed Web of Science ®Google Scholar
• ACHARYA SS, DIMICHELE DM: Management of Factor VIII inhibitors. Best Pract. Res. Clin. Haematol. (2006) 19:51-66.
   PubMed Web of Science ®Google Scholar
• ASTERMARK J, MORADO M, ROCINO A et al.: Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia (2006) 12:363-371.
   PubMed Web of Science ®Google Scholar
• BERNTORP E: Immune tolerance induction: recombinant versus human-derived product. Haemophilia (2001) 7:109-113.
   PubMed Web of Science ®Google Scholar
• KREUZ W, ETTINGSHAUSEN CE, ZYSCHKA A et al.: Inhibitor development in previously untreated patients with haemophila A: a prospective long-term follow-up comparing plasma derived and recombinant products. Semin. Thromb. Haemost. (2002) 28:285-290.
   PubMed Web of Science ®Google Scholar
• GRINGERI A, MANNUCCI PM: Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. For Italian Association of Haemophilia Centres. Thromb. Haemost. (2005) 11:611-619.
   Google Scholar
• STASI R, BRUNETTI M, STIPA E, AMADORI S: Selective B cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood (2004) 103:4424-4428.
   PubMed Web of Science ®Google Scholar
• CARCAO M, ST LOUIS J, POON MC et al.: Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. On behalf of the Inhibitor Subcommittee of the Association of Haemophilia Clinic Directors of Canada. Haemophilia (2006) 12:7-18.
   PubMed Web of Science ®Google Scholar
• MATHIAS M, KHAIR K, HANN I et al.: Rituximab in the treatment of alloimmune Factor VIII and IX antibodies in two children with severe haemophilia. Br. J. Haematol. (2004) 125:366-368.
   PubMed Web of Science ®Google Scholar
• PIPE SW: The promise and challenges of bioengineered recombinant clotting factors. J. Thromb. Haemost. (2005) 3:1692-701.
   PubMed Web of Science ®Google Scholar
• MIAO HZ, SIRANCHAINAN N, PALMER L et al.: Bioengineering of coagulant FVIII for improved secretion. Blood (2004) 103:3412-3419.
   PubMed Web of Science ®Google Scholar
• SAENKO EL, PIPE SW: Strategies towards a longer acting Factor VIII. Haemophilia (2006) 12(Suppl. 3):42-51.
   PubMed Web of Science ®Google Scholar
• MOLINEUX G: Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy (2003) 23:3S-8S.
   PubMed Web of Science ®Google Scholar
• BARU M, CARMEL-GOREN L, BARENHOLZ Y et al.: Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb. Haemost. (2005) 93:1061-1068.
   PubMed Web of Science ®Google Scholar
• PIPE SW, KAUFMAN RJ: Characterization of a genetically engineered inactivation resistant coagulation Factor VIIIa. Proc. Natl. Acad. Sci. USA (1997) 94:11851-6.
   PubMed Web of Science ®Google Scholar
• SAENKO EL, YAKHYAEV AV, MIKHAILENKO I et al.: Role of the low density lipoprotein-related protein receptor in mediation of Factor VIII catabolism. J. Biol. Chem. (1999) 274:37685-92.
   PubMed Web of Science ®Google Scholar
• BOVENSCHEN N, MERTENS K, HU L et al.: LDL receptor cooperates with LDL receptor related protein in regulating plasma levels of coagulation Factor VIII in vivo. Blood (2005) 106:906-912.
   PubMed Web of Science ®Google Scholar
• LUBIN IM, HEALEY JF, BARROW RT, SCANDELLA D, LOLLAR P: Analysis of the human Factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J. Biol. Chem. (1997) 272:30191-30195.
   PubMed Web of Science ®Google Scholar
• BARROW RT, HEALEY JF, GAILANI D, SCANDELLA D, LOLLAR P: Reduction of antigenicity of FVIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine Factor VIII molecules. Blood (2000) 95:564-568.
   PubMed Web of Science ®Google Scholar
• GRAW J, BRACKMANN HH, OLDENBURG J, SCHNEPPENHEIM R, SPANNAG M, SCHWAAB R: Haemophilia A: from mutation analysis to new therapies. Nature (2005) 6:488-501.
   Web of Science ®Google Scholar
• NATHWANI AC, BENJAMIN R, NIENHUIS AW, DAVIDOFF AM: Current status and prospects for gene therapy. Vox Sanguinis (2004) 87:73-81.
   PubMed Web of Science ®Google Scholar
• LILLICRAP D, VANDENDRIESSCHE T, HIGH K: Cellular and genetic therapies for haemophilia. Haemophilia (2006) 12(Suppl. 3):36-41.
   PubMed Web of Science ®Google Scholar
• HIGH KA, MANNO CS, SABATINO DE et al.: Immune responses to AAV and to FIX in a Phase I study of AAV mediated, liver directed gene transfer for hemophilia B. Blood (2003) 102:154a.
   Google Scholar
• KAZAZIAN HH JR: An estimated frequency of endogenous insertional mutations in humans. Nat. Genet. (1999) 22:130.
   PubMed Web of Science ®Google Scholar
• EHRHARDT A, KAY MA: A new adenoviral helper dependent vector results in long term therapeutic levels of human coagulation Factor IX at low doses in vivo. Blood (2002) 99:3923-3930.
   PubMed Web of Science ®Google Scholar
• HACEIN BEY ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2 associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302:415-419.
   PubMed Web of Science ®Google Scholar
• SORENSEN B, INGERSLEV J: Thromboelastography and recombinant Factor VIIa hemophilia and beyond. Semin. Hematol. (2004) 41(Suppl. 1):140-144.
   PubMed Web of Science ®Google Scholar
• SORENSEN B, INGERSLEV J: Tailoring haemostatic treatment to patient requirements – an update on monitoring haemostatic response using thromboelastography. Haemophilia (2005) 11:1-6.
   PubMedGoogle Scholar
• SIEGEMUND T, PETROS S, SIEGEMUND A et al.: Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb. Haemost. (2003) 90(5):781-786.
   PubMed Web of Science ®Google Scholar
• HEMKER HC, GIESEN P, AL DIERI R et al.: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. (2003) 33:4-15.
   PubMed Web of Science ®Google Scholar
• DARGAUD Y, BEGUIN S, LIENHART A et al.: Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. (2005) 93:475-480.
   PubMed Web of Science ®Google Scholar
• DARGAUD Y, BORDET JC, BAGLIN T et al.: Monitoring of FVIII-FIX by-passing agents by calibrated automated thrombin generation test. Haematologica (2006) 12(Suppl. 2):14 (Abstract PO 376).
   Google Scholar
• KAY MA, MANNO CS, RAGNI MV et al.: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. (2000) 24(3):257-261.
   PubMed Web of Science ®Google Scholar
• ROTH DA, TAWA NE JR, O'BRIEN JM et al.: Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. Factor VIII Transkaryotic Therapy Study Group. N. Engl. J. Med. (2001) 344:1735-1742.
   PubMed Web of Science ®Google Scholar
• POWELL JS, RAGNI MV, WHITE GC 2ND et al.: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102:2038-2045.
   PubMed Web of Science ®Google Scholar
• MANNO CS, MANNO CS, ARRUDA VR et al.: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. (2006) 12:342-347.
   PubMed Web of Science ®Google Scholar
• JIANG H, PIERCE GF, OZELO MC et al.: Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. (2006) 14:452-455.
   PubMed Web of Science ®Google Scholar
• LU DR, ZHOU JM, ZHENG B et al.: Stage I clinical trial of gene therapy for hemophilia B. Sci. China B (1993) 36:1342-1351.
   PubMedGoogle Scholar